ClearPoint Neuro (CLPT) Common Equity (2011 - 2026)

ClearPoint Neuro (CLPT) has 16 years of Common Equity data on file, last reported at $18.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 5.73% year-over-year to $18.8 million; the trailing twelve-month figure through Mar 2026 stood at $18.8 million (down 5.73% YoY), and the FY2025 full-year result was $28.0 million, up 10.36% from the prior year.
• Common Equity fell to $18.8 million in Q1 2026, from $28.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $45.7 million in Q1 2022 to a low of $15.9 million in Q3 2025.
• A 5-year average of $29.1 million and a median of $28.0 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity climbed 20.37% in 2024 and slumped 45.26% in 2025, its largest moves.
• Tracing CLPT's Common Equity over 5 years: stood at $36.9 million in 2022, then tumbled by 42.6% to $21.2 million in 2023, then advanced by 19.91% to $25.4 million in 2024, then climbed by 10.36% to $28.0 million in 2025, then tumbled by 32.76% to $18.8 million in 2026.
• Business Quant data shows CLPT's Common Equity at $18.8 million in Q1 2026, $28.0 million in Q4 2025, and $15.9 million in Q3 2025.